Sernova (XTER:PSH) Debt-to-Revenue : N/A (As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sernova Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Sernova's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.09 Mil. Sernova's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.55 Mil. Sernova's annualized Revenue for the quarter that ended in Jan. 2024 was C$0.00 Mil.

Sernova Debt-to-Revenue Historical Data

The historical data trend for Sernova's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Debt-to-Revenue Chart

Sernova Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

Sernova Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Revenue	Get a 7-Day Free Trial															N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Sernova's Debt-to-Revenue

For the Biotechnology subindustry, Sernova's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sernova's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sernova's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sernova's Debt-to-Revenue falls into.

Sernova Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Sernova's Debt-to-Revenue for the fiscal year that ended in Oct. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.136	+	0)	/	N/A
	=	N/A

Sernova's annualized Debt-to-Revenue for the quarter that ended in Jan. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.088	+	0.546)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jan. 2024) Revenue data.

Sernova Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sernova's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sernova (XTER:PSH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Corp (XTER:PSH) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

SEOVF:USA PSH:Germany SVA:Canada

Address

700 Collip Circle, The Stiller Centre, Suite 114, London, ON, CAN, N6G 4X8

Website

https://www.sernova.com

Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and or hormones for the long-term treatment of multiple serious, chronic diseases such as diabetes, hemophilia, and thyroid disease.